Higher Serum Uric Acid is a Risk Factor of Reduced Muscle Mass in Men with Type 2 Diabetes Mellitus

Abstract

Objective Sarcopenia has been recognized as a diabetic complication, and hyperuricemia is often accompanied by type 2 diabetes mellitus (T2DM). However, it is unknown whether serum uric acid (UA) levels are associated with reduced muscle mass in T2DM.

Methods We conducted a cross-sectional study to investigate the association of serum UA with muscle mass in 401 subjects with T2DM (209 men and 192 postmenopausal women). The relative skeletal muscle mass index (RSMI) was evaluated using whole-body dual-energy x-ray absorptiometry.

Results Multiple regression analyses adjusted for body weight, age, serum creatinine, hemoglobin A1c (HbA1c), and duration of T2DM showed that serum UA was negatively associated with RSMI in all subjects and men with T2DM (β=−0.13, p=0.001 and β=−0.17, p=0.003, respectively). Moreover, logistic regression analyses adjusted for these confounding factors showed that a higher serum UA level was significantly associated with low RSMI in men with T2DM [odds ratio (OR)=1.94, 95% confidence interval (CI)=1.10–3.45 per SD increase, p=0.023]. In addition, higher serum UA levels were significantly associated with low RSMI after additional adjustment for age, duration of T2DM, HbA1c level, serum creatinine level, and sex in all subjects with T2DM [OR=1.80, 95% CI=1.20–2.72 per SD increase, p=0.005].

Conclusions The present study showed for the first time that higher serum UA is an independent risk factor of reduced muscle mass in men with T2DM.

Key words

uric acid - hyperuricemia - muscle mass - sarcopenia - diabetes mellitus

• References

• 1 da Rocha Fernandes J, Ogurtsova K, Linnenkamp U. et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract 2016; 117: 48-54
• 2 Meigs JB. Epidemiology of type 2 diabetes and cardiovascular disease: Translation from population to prevention: the Kelly West award lecture 2009. Diabetes Care 2010; 33: 1865-1871
• 3 Jaacks LM, Siegel KR, Gujral UP. et al. Type 2 diabetes: A 21^st century epidemic. Best Pract Res Clin Endocrinol Metab 2016; 30: 331-343
• 4 Ginter E, Simko V. Global prevalence and future of diabetes mellitus. Adv Exp Med Biol 2012; 771: 35-41
• 5 Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21^st century. Adv Exp Med Biol 2012; 771: 42-50
• 6 Colberg SR, Sigal RJ, Fernhall B. et al. Exercise and Type 2 Diabetes: The American College of Sports Medicine and the American Diabetes Association: Joint position statement. Diabetes Care 2010; 33: e147-e167
• 7 Andersen H, Nielsen S, Mogensen CE. et al. Muscle strength in type 2 diabetes. Diabetes 2004; 53: 1543-1547
• 8 Tajiri Y, Kato T, Nakayama H. et al. Reduction of skeletal muscle, especially in lower limbs, in Japanese type 2 diabetic patients with insulin resistance and cardiovascular risk factors. Metab Syndr Relat Disord 2010; 8: 137-142
• 9 Park SW, Goodpaster BH, Lee JS. et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 2009; 32: 1993-1997
• 10 Park SW, Goodpaster BH, Strotmeyer ES. et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: The health, aging, and body composition study. Diabetes Care 2007; 30: 1507-1512
• 11 Adams GR, McCue SA. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol 1998; 84: 1716-1722
• 12 Kostka T, Arsac LM, Patricot MC. et al. Leg extensor power and dehydroepiandrosterone sulfate, insulin-like growth factor-I and testosterone in healthy active elderly people. Eur J Appl Physiol 2000; 82: 83-90
• 13 Frystyk J, Skjaerbaek C, Vestbo E. et al. Circulating levels of free insulin-like growth factors in obese subjects: The impact of type 2 diabetes. Diabetes Metab Res Rev 1999; 15: 314-322
• 14 Tanaka K, Kanazawa I, Sugimoto T. Reduction in endogenous insulin secretion is a risk factor of sarcopenia in men with type 2 diabetes mellitus. Calcif Tissue Int 2015; 97: 385-390
• 15 Tanaka K, Kanazawa I, Yamaguchi T. et al. Active vitamin D possesses beneficial effects on the interaction between muscle and bone. Biochem Biophys Res Commun 2014; 450: 482-487
• 16 Glantzounis GK, Tsimoyiannis EC, Kappas AM. et al. Uric acid and oxidative stress. Curr Pharm Des 2005; 11: 4145-4151
• 17 Lippi G, Montagnana M, Franchini M. et al. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008; 392: 1-7
• 18 Verdecchia P, Schillaci G, Reboldi G. et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072-1078
• 19 Johnson RJ, Kang DH, Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 2003; 41: 1183-1190
• 20 Beavers KM, Beavers DP, Serra MC. et al. Low relative skeletal muscle mass indicative of sarcopenia is associated with elevations in serum uric acid levels: Findings from NHANES III. J Nutr Health Aging 2009; 13: 177-182
• 21 Garcia-Esquinas E, Guallar-Castillon P, Carnicero JA. et al. Serum uric acid concentrations and risk of frailty in older adults. Exp Gerontol 2016; 82: 160-165
• 22 Beberashvili I, Sinuani I, Azar A. et al. Serum uric acid as a clinically useful nutritional marker and predictor of outcome in maintenance hemodialysis patients. Nutrition 2015; 31: 138-147
• 23 Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is amarker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2011; 22: 1191-1198
• 24 Kanazawa I, Yamamoto M, Yamaguchi T. et al. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 362-365
• 25 Seino Y, Nanjo K, Tajima N. et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 2010; 1: 2-20
• 26 Cruz-Jentoft AJ, Baeyens JP, Bauer JM. et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423
• 27 Chen LK, Liu LK, Woo J. et al. Sarcopenia in Asia: Consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 2014; 15: 95-101
• 28 Visser M, Pahor M, Taaffe DR. et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: The Health ABC Study. J Gerontol A Biol Sci Med Sci 2002; 57: M326-M332
• 29 Doria E, Buonocore D, Focarelli A. et al. Relationship between human aging muscle and oxidative system pathway. Oxid Med Cell Longev 2012; 2012: 830257
• 30 Okuno H, Kishimoto KN, Hatori M. et al. 1α,25-dihydroxyvitamin D₃ enhances fast-myosin heavy chain expression in differentiated C2C12 myoblasts. Cell Biol Int 2012; 36: 441-447
• 31 Garcia LA, King KK, Ferrini MG. et al. 1,25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology 2011; 152: 2976-2986
• 32 Chen W, Roncal-Jimenez C, Lanaspa M. et al. Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. Metabolism 2014; 63: 150-160
• 33 Takahashi S, Yamamoto T, Moriwaki Y. et al. Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. Adv Exp Med Biol 1998; 431: 57-60
• 34 Scragg R, Holdaway I, Singh V. et al. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract 2007; 27: 181-188
• 35 Gupta A, Aslam M, Rathi S. et al. Association of Vitamin D Levels and type 2 Diabetes Mellitus in Asian Indians is Independent of Obesity. Exp Clin Endocrinol Diabetes 2018; 126: 553-558